Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
US11111223B2 · kind B2 · utility
1Cited by
0References
36Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 14, 2017 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Feb 14, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.